Market Cap
US$2.8b
Last Updated
2019/09/22 00:54 UTC
Data Sources
Company Financials +
Executive Summary
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally.
Snowflake
Fundamentals
Reasonable growth potential with mediocre balance sheet.
Risks
- Nevro has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Nevro's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.08%
NVRO
1.1%
US Medical Equipment
-0.6%
US Market
1 Year Return
51.8%
NVRO
9.9%
US Medical Equipment
0.6%
US Market
NVRO outperformed the Medical Equipment industry which returned 9.9% over the past year.
NVRO outperformed the Market in United States of America which returned 0.6% over the past year.
Share holder returns
| NVRO | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.08% | 1.1% | -0.6% |
| 30 Day | 9.1% | 0.6% | 2.2% |
| 90 Day | 40.4% | 2.9% | 1.1% |
| 1 Year | 51.8%51.8% | 10.8%9.9% | 2.9%0.6% |
| 3 Year | -11.9%-11.9% | 70.1%64.9% | 44.6%35.2% |
| 5 Year | n/a | 138.9%111.8% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Nevro's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
If You Had Bought Nevro (NYSE:NVRO) Shares A Year Ago You'd Have Made 33%1 month ago | Simply Wall St
Should You Take Comfort From Insider Transactions At Nevro Corp. (NYSE:NVRO)?2 months ago | Simply Wall St
Is Nevro (NYSE:NVRO) Using Too Much Debt?Valuation
Is Nevro undervalued based on future cash flows and its price relative to the stock market?
35%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Nevro's share price is below the future cash flow value, and at a moderate discount (> 20%).
Nevro's share price is below the future cash flow value, but not at a substantial discount (< 40%).
Price Based on Earnings
Nevro is loss making, we can't compare its value to the US Medical Equipment industry average.
Nevro is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Nevro, we can't assess if its growth is good value.
Price Based on Value of Assets
Nevro is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Nevro expected to perform in the next 1 to 3 years based on estimates from 11 analysts?
39.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Nevro's revenue is expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
Nevro's earnings are expected to grow significantly at over 20% yearly.
Nevro's revenue growth is expected to exceed the United States of America market average.
Nevro's earnings growth is expected to exceed the United States of America market average.
Nevro's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Nevro will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Next Steps
Past Performance
How has Nevro performed over the past 5 years?
-9.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Nevro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Nevro's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Nevro's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Nevro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Nevro has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Nevro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Nevro's financial position?
Financial Position Analysis
Nevro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Nevro's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Nevro's level of debt (77.5%) compared to net worth is high (greater than 40%).
Unable to establish if Nevro's debt level has increased without past 5-year debt data.
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 2.6x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Nevro has sufficient cash runway for more than 3 years based on current free cash flow.
Unable to confirm if Nevro has at least 1 year of cash runway based on growing free cash flows without relevant data.
Next Steps
Dividend
What is Nevro's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Nevro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Nevro's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Nevro has not reported any payouts.
Unable to verify if Nevro's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Nevro has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Nevro's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Nevro's salary, the management and board of directors tenure and is there insider trading?
2.5yrs
Average management tenure
CEO
D. Grossman (59yo)
0.5yrs
Tenure
Mr. D. Keith Grossman serves as a President, Chief Executive Officer and Director at Nevro Corp. since March 19, 2019 and as its Chairman of the Board since May 20, 2019. He is a Director of Alcon, Inc. He ...
Management Age and Tenure
2.5yrs
Average Tenure
58.5yo
Average Age
The tenure for the Nevro management team is about average.
Board Age and Tenure
2.5yrs
Average Tenure
62.5yo
Average Age
The average tenure for the Nevro board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 8,183 |
| Max Price | US$61.45 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 1,675 |
| Max Price | US$60.00 |
Ownership Breakdown
Management Team
Andrew Galligan (63yo)
Chief Financial Officer
- Tenure: 9.3yrs
- Compensation: US$693.26k
D. Grossman (59yo)
Chairman of the Board
- Tenure: 0.5yrs
Doug Alleavitch (58yo)
Vice President of Quality
- Tenure: 4.4yrs
- Compensation: US$1.16m
Lori Ciano
Chief Human Resources Officer
- Tenure: 0.3yrs
David Caraway (62yo)
Chief Medical Officer
- Tenure: 5.4yrs
Juliet Cunningham
Vice President of Investor Relations
- Tenure: 0.7yrs
Patrick Schmitz (59yo)
Vice President of Operations
- Tenure: 3.5yrs
- Compensation: US$1.16m
Neeraj Teotia (44yo)
Vice President of Marketing
- Tenure: 3.3yrs
Kashif Rashid (45yo)
General Counsel
- Tenure: 1.8yrs
- Compensation: US$1.87m
Michael Carter (47yo)
Vice President of Global Sales
- Tenure: 0.6yrs
Board Members
Brad Vale (66yo)
Independent Director
- Tenure: 4.5yrs
- Compensation: US$337.94k
Frank Fischer (77yo)
Independent Director
- Tenure: 6.9yrs
- Compensation: US$341.94k
Shawn McCormick (55yo)
Independent Director
- Tenure: 5yrs
- Compensation: US$354.94k
Bess Weatherman (59yo)
Director
- Tenure: 0.5yrs
Wilf Jaeger (64yo)
Independent Director
- Tenure: 7.7yrs
- Compensation: US$360.19k
D. Grossman (59yo)
Chairman of the Board
- Tenure: 0.5yrs
Michael DeMane (62yo)
Lead Director
- Tenure: 0.3yrs
- Compensation: US$379.94k
Kevin O'Boyle (63yo)
Director
- Tenure: 0.5yrs
Company Information
Nevro Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nevro Corp.
- Ticker: NVRO
- Exchange: NYSE
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$2.777b
- Shares outstanding: 30.89m
- Website: https://www.nevro.com
Number of Employees
Location
- Nevro Corp.
- 1800 Bridge Parkway
- Redwood City
- California
- 94065
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NVRO | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Nov 2014 |
| 1N7 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2014 |
Biography
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/22 00:54 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.